Skip to content
logo MSD Oncology Clinical Trials
  • Home
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Esophageal
    • Gastric
    • Gynecologic
    • Head and Neck
    • Hematologic
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Pediatric
    • Prostate
    • Solid Tumors
  • About
  • Common Questions
  • For HCPs
  • English
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Study Keyword: PD1

The purpose of this study is to characterize the pharmacokinetic (PK) profile of pembrolizumab (MK-3475) following single subcutaneous (SC) injection of pembrolizumab Dose A versus pembrolizumab Dose C in adults with advanced melanoma. Additionally, the safety and tolerability of pembrolizumab SC injections will be assessed. And, finally, the efficacy of pembrolizumab intravenous (IV) infusion administration will be assessed.

Study Keyword: PD1

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab in Participants With Advanced Melanoma

May 20, 2022

By Tyler Kalist

The purpose of this study is to characterize the pharmacokinetic (PK) profile of pembrolizumab (MK-3475) following single subcutaneous (SC) injection of pembrolizumab Dose A versus pembrolizumab Dose C in adults with

A Study of Pembrolizumab in Relapsed or Refractory Classical Hodgkin’s Lymphoma or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

March 10, 2022

By Support_Clique

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in

Safety and Efficacy of Pembrolizumab in Children and Young Adults With Classical Hodgkin Lymphoma

March 10, 2022

By clique_admin

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early

A Study of Pembrolizumab in Pediatric Participants With an Advanced Solid Tumor or Lymphoma

March 10, 2022

By clique_admin

This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have any of the following types of cancer: advanced melanoma (6 months to

Study of Pembrolizumab Combination Therapies in Metastatic Castration-Resistant Prostate Cancer

March 7, 2022

By Support_Clique

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will be nine cohorts

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab in Adults With Tyrosine Kinase Inhibitor- -Resistant Epidermal Growth Factor Receptor- -Mutated Metastatic Non-squamous Non-small Cell Lung Cancer

March 7, 2022

By Tyler Kalist

The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer

March 7, 2022

By clique_admin

This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer

March 7, 2022

By Support_Clique

This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who

Study of Pembrolizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

March 7, 2022

By Support_Clique

This is a study of pembrolizumab (MK-3475) for participants with relapsed/refractory classical Hodgkin Lymphoma (RRcHL) who: 1) have failed to achieve a response or progressed after autologous stem cell transplant (auto-SCT)

Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma

March 7, 2022

By Support_Clique

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal

Posts navigation

Older posts
logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

eSSENTIAL Accessibility

eSSENTIAL Accessibility